SPRAVATO Induction Capacity Math: Why New Starts Consume More Chair Time Than Teams Expect (2026)
The headline operational mistake in SPRAVATO planning is assuming the bottleneck is spray administration. The primary sources point somewhere else: front-loaded induction frequency plus required monitoring creates a chair-time problem first and a staffing problem second.
The first four weeks are heavier than many programs model
The current prescribing information for treatment-resistant depression says SPRAVATO is dosed twice weekly during weeks 1 through 4, then once weekly during weeks 5 through 8, and after week 9 at the least frequent cadence needed to maintain response. On the REMS side, every outpatient session still requires direct observation and at least two hours of monitoring.
Original insight: one new start creates at least 16 monitored chair-hours in the induction month alone
Twice-weekly treatment for four weeks means eight visits in the induction phase. With a minimum two-hour monitoring requirement, that is at least 16 monitored chair-hours before you count intake, blood pressure workflow, discharge readiness, or room turnover. If you model capacity only by daily appointment slots, you miss the actual choke point.
The eight-week picture is even more useful for planning
Add the weekly visits from weeks 5 through 8 and a single new treatment-resistant depression start reaches twelve visits in the first eight weeks. That is at least 24 monitored chair-hours per patient before any operational overhead. The practical implication is that new-start growth can overwhelm a clinic even when the census still looks small on paper.
Why this matters strategically
- Induction-heavy weeks distort staffing demand: nurse and provider coverage rise faster than active-patient counts suggest.
- New starts are not equivalent to maintenance patients: a clinic can be "full" on monitored time well before it looks full on patient volume.
- Scheduling errors compound quickly: one delayed induction visit can push pressure into the next clinic block because monitoring windows overlap.
- Throughput planning should start with monitored hours, not visit counts: visit counts hide the real resource burn.
What the EHR should show program leaders every week
- Induction visits vs. maintenance visits scheduled over the next 14 days.
- Total monitored chair-hours booked by clinic day.
- Average turnover time between monitored sessions.
- Monitoring forms still awaiting submission inside the seven-day REMS window.
How to use the math operationally
Separate capacity planning into at least two streams: new starts and maintenance volume. If leadership tracks only "number of SPRAVATO patients," they are likely to expand referrals before they have the chair coverage to absorb induction demand. Programs should forecast intake growth against monitored-chair hours first, then confirm staff coverage, and only then open additional referral slots.
Bottom line
The biggest strategic insight in the latest SPRAVATO materials is that induction intensity drives capacity more than census does. Programs that model monitored hours instead of just visits will make better decisions about staffing, referral growth, and clinic-block design.
Next Steps
Editorial Standards
Last reviewed:
Methodology
- Used the current SPRAVATO prescribing information to define induction and maintenance dosing cadence for treatment-resistant depression.
- Used REMS outpatient requirements and the current patient monitoring form to anchor minimum monitoring obligations per visit.
- Added original monitored-chair-hour calculations to translate source requirements into planning math for outpatient operators.